Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A02478-47 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to compare Emergency Department patients who undergo influenza and RSV PCR testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) located in the ED, to patients who undergo influenza and RSV PCR testing at the core laboratory.
The principal purpose is to determine if the time spent in the ED is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing.
In order to reduce the bias of this study, it has been established :
After verification of the eligibility criteria and obtaining the written consent of the patient, a randomization procedure will be initiated for the patient. Randomization will be centralized at the DRCI of Clermont-Ferrand University Hospital. Patients will be randomly assigned to one of the study groups by means of individual block randomization. A document describing the randomization procedure will be kept confidentially in the DRCI of Clermont-Ferrand University Hospital;
- The collection of data will be prospective.
A listing of patients opposing to the study's participation to verify that their characteristics are homogeneous to the general population The choice of the Genexpert® automaton used in the "point of care testing" arm whose principle of operation requires a minimum of manipulations (<2 minutes) and does not generate inter-operator variability Statistical analyzes will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at the risk of error of the first species α of 5%. Part of the analysis of the secondary endpoints should be primarily exploratory in nature. As discussed by Feise in 2002 (Feise RJ, Do 2: 8), the adjustment of the risk of error of 1st species will not be proposed systematically, but case by case in view of clinical considerations and not just statistical ones.
Continuous variables will be presented as mean and standard deviation, subject to the normality of their distribution (Shapiro-Wilk test if necessary). In case of non-normality, they will be presented as median, quartiles, and extreme values. The qualitative variables will be expressed in numbers and percentages associated. Graphic representations will be associated with these analyzes as much as possible.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Point-of-care testing arm | Experimental | for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7. |
|
| Core Lab testing arm | Active Comparator | for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rapid diagnosis of influenza in the emergency medical service | Diagnostic Test | Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing). |
| Measure | Description | Time Frame |
|---|---|---|
| Time of care in the adult emergency department | Emergency care time, calculated from the time of first medical-care contact to the time of release of the adults emergency department. This time will be calculated from the data collected on the standardized questionnaire | through study completion, an average of 1 week |
| Measure | Description | Time Frame |
|---|---|---|
| Prescription of antibiotics initiated at the adults emergency department | nature of antibiotics | within 72 hours after taking care of the patient |
| Duration of the prescription of antibiotics initiated at the adults emergency department |
Not provided
Inclusion criteria :
Exclusion criteria :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cécile Henquell, PU-PH | University Hospital, Clermont-Ferrand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Clermont-Ferrand | Clermont-Ferrand | Auvergne | 63003 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26788921 | Background | Soto M, Sampietro-Colom L, Vilella A, Pantoja E, Asenjo M, Arjona R, Hurtado JC, Trilla A, Alvarez-Martinez MJ, Mira A, Vila J, Marcos MA. Economic Impact of a New Rapid PCR Assay for Detecting Influenza Virus in an Emergency Department and Hospitalized Patients. PLoS One. 2016 Jan 20;11(1):e0146620. doi: 10.1371/journal.pone.0146620. eCollection 2016. | |
| 29137903 |
| Label | URL |
|---|---|
| Procédure actualisée de prise en charge globale d'un patient suspect de grippe saisonnière | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
duration of treatment (day)
| within 72 hours after taking care of the patient |
| Posology of antibiotics initiated at the adults emergency department | posology (mg) | within 72 hours after taking care of the patient |
| Costs of antibiotics initiated at the adults emergency department | associated costs (euros) | within 72 hours after taking care of the patient |
| Prescription of antiviral initiated in adults emergency department | nature of antiviral prescription | within 72 hours after taking care of the patient |
| Duration of the specific antiviral prescription initiated in adults emergency department | duration of treatment (day) | within 72 hours after taking care of the patient |
| Costs of specific antiviral prescription initiated in adults emergency department | associated costs (euros) | within 72 hours after taking care of the patient |
| Type of prescription of imaging tests at the adults emergency department | type of examinations related to the patient respiratory pathology | within 72 hours after taking care of the patient |
| Number of prescription of imaging tests at the adults emergency department | Number of examinations related to the patient respiratory pathology | within 72 hours after taking care of the patient |
| Costs of the prescription of imaging tests at the adults emergency department | Costs of examinations related to the patient respiratory pathology (euros) | within 72 hours after taking care of the patient |
| Type of prescription of biology examinations | type of laboratory examinations related to respiratory pathology | within 72 hours after taking care of the patient |
| Number of prescription of biology examinations | Number of laboratory examinations related to respiratory pathology | within 72 hours after taking care of the patient |
| Costs of prescription of biology examinations | Costs of laboratory examinations related to respiratory pathology (euros) | within 72 hours after taking care of the patient |
| Trabattoni E, Le V, Pilmis B, Pean de Ponfilly G, Caisso C, Couzigou C, Vidal B, Mizrahi A, Ganansia O, Le Monnier A, Lina B, Nguyen Van JC. Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED. Am J Emerg Med. 2018 Jun;36(6):916-921. doi: 10.1016/j.ajem.2017.10.046. Epub 2017 Oct 18. |
| 28392237 | Background | Brendish NJ, Malachira AK, Armstrong L, Houghton R, Aitken S, Nyimbili E, Ewings S, Lillie PJ, Clark TW. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017 May;5(5):401-411. doi: 10.1016/S2213-2600(17)30120-0. Epub 2017 Apr 6. |
| 30207514 | Background | Ho YII, Wong AH, Lai RWM. Comparison of the Cepheid Xpert Xpress Flu/RSV Assay to in-house Flu/RSV triplex real-time RT-PCR for rapid molecular detection of Influenza A, Influenza B and Respiratory Syncytial Virus in respiratory specimens. J Med Microbiol. 2018 Nov;67(11):1576-1580. doi: 10.1099/jmm.0.000841. Epub 2018 Sep 12. |
| 30185508 | Background | Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children. J Clin Microbiol. 2018 Oct 25;56(11):e00930-18. doi: 10.1128/JCM.00930-18. Print 2018 Nov. |
| 30026005 | Background | Bennett S, MacLean A, Gunson R. Verification of Cepheid Xpert Xpress Flu/RSV assay for use with gargle samples, sputa and endotracheal secretions. J Hosp Infect. 2019 Jan;101(1):114-115. doi: 10.1016/j.jhin.2018.07.016. Epub 2018 Jul 17. No abstract available. |
| 29769281 | Background | Popowitch EB, Miller MB. Comparison of the Xpert Flu/RSV XC and Xpress Flu/RSV Assays. J Clin Microbiol. 2018 Jul 26;56(8):e00278-18. doi: 10.1128/JCM.00278-18. Print 2018 Aug. |
| Nucleic Acid Detection Based Tests | View source |
| Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection | View source |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |